<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197076</url>
  </required_header>
  <id_info>
    <org_study_id>Neoadjuvant study of NSCLC</org_study_id>
    <nct_id>NCT04197076</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA</brief_title>
  <official_title>An Open, Observational Clinical Study, 2 Cycles Treatment as Neoadjuvant Therapy for NSCLC With Stage IIIA (T1-2N2, T3N1, T4N0-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in
      stage IIIA NSCLC patients.（Interventional study）
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, observational clinical study, 2 cycles treatment will be planned as
      neo-adjuvant therapy for NSCLC participants in stage IIIA (T1-2N2, T3N1, T4N0-1).

      Study design:

      Newly diagnosed Resectable IIIa NSCLC EGFR/ALK/ROS1 TEST PD-L1 TEST Collect puncture biopsy
      tissue/ Blood sample in screening period Chest enhanced CT Conditions allowed， whole body
      PETCT Exam; Group A：Targeted therapy Tumors with Driver genes （EGFR/ALK/ROS1 Positive） 2
      cycles（42 days; Group B：Immunotherapy Enroll Patients from 816 Research treated with
      Neoadjuvant immunotherapy Or, treated with immunotherapy in practice（with approval） Group
      C：Routine Chemotherapy Driver genes（EGFR/ALK/ROS1 Negative） and PD-L1 Test negative;
      Operation （within 6 Ws postoperation） Standard treatment， Allow adjuvant chemotherapy±radioth
      erapy Collect resected tissue sample(Tumor T and Node N) /Blood sample; comparisons before
      and after treatment: Imaging：CT、PETCT Sample：Tumor tissue、blood

      Objective and End point:

        1. Main objective and end point：DFS，pCR rate

        2. Second objective and end point：OS

        3. Exploratory objective and end point：cRR rate、relevant AE、Change of Scoring
           Scale、exploration for relevant biological indicators
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DFS: disease free survival</measure>
    <time_frame>36 months</time_frame>
    <description>The time length from randomization(mainly from the receipt of pathology and genetic diagnosis reports)to any of the following events: disease progression, disease recurrence or death from any cause. Disease progression or relapse will be assessed according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pCR: pathologic complete response</measure>
    <time_frame>36 months</time_frame>
    <description>the proportion of patients achieved pathologic complete response（lung and lymph node without tumor residual assessed by pathology review)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS: Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>The time length from the date of randomization (according to the received pathology and genetic diagnosis report) to the date of death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cRR rates</measure>
    <time_frame>approximately 10 weeks After surgery</time_frame>
    <description>The proportion of patients achieved complete or patial remission(Imageological) according to RECIST 1.1 prior to definitive surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Safty AEs</measure>
    <time_frame>36 months</time_frame>
    <description>proportion of delayed or cancelled surgery or duration of surgery or length of hospitalization or surgical procedure, and incidence of AE/SAE associated with surgery, Adverse events will be graded according to NCI CTCAE</description>
  </other_outcome>
  <other_outcome>
    <measure>Qol Quality of Life</measure>
    <time_frame>36 months</time_frame>
    <description>Quality of life asscesed by Quality of Life Questionnare-Core 30(EORTC QLQ-C30）of The European O-rganization for Reasearch and Treatment of Cancer containing 30 items in total. Among them, items 29 and 30 are divided into seven grades. According to the answer options 1 to 7 points. Other items are divided into four grades: none, one point, some to many. When scoring, they are directly rated 1 to 4 points. For functional and overal health domain, higher score means better life quality; for symptom domain ,higher score means worse life quality.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant immunotherapy</arm_group_label>
    <description>pd-1 or pd-l1 inhabitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant targeted therapy</arm_group_label>
    <description>TKIs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <description>chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 or anti-PD-L1</intervention_name>
    <description>immunotherapy anti-PD-1 or anti-PD-L1</description>
    <arm_group_label>Neoadjuvant immunotherapy</arm_group_label>
    <other_name>Neoadjuvant immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR-TKI, ALK inhibitor, ROS1 inhibitor</intervention_name>
    <description>targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor</description>
    <arm_group_label>Neoadjuvant targeted therapy</arm_group_label>
    <other_name>Neoadjuvant targeted therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>investigator decided</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Neoadjuvant chemotherapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Subject's tumor sample obtained within 3 months before enrollment is suitable to be used for
      gene testing（EGFR/ALK/ROS1）and PD-L1 testing with Immunohistochemistry (IHC)。
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC participants in stage IIIA (T1-2N2, T3N1, T4N0-1)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary non-small cell lung cancer confirmed by cytology or histology

          2. According to the TNM stage (8th Edition) of IASLC lung cancer, it is determined to be
             IIIA stage (t1-2n2, t3n1, t4n0-1) non-small cell lung cancer, which is considered to
             be resectable;

          3. There must be at least one evaluable focus judged according to rrecist1.1 standard
             (the longest diameter on spiral CT is at least 10 mm, and the longest diameter on
             general CT is at least 20 mm)

          4. ECoG PS 0 or 1

          5. There are tumor samples available for gene detection (EGFR / ALK / ros1) and PD-L1
             immunohistochemistry (IHC) in the subjects, and the tumor samples should be obtained
             within 3 months before enrollment.

          6. If all suspected mediastinal lymph nodes (including those with pathological
             enlargement or FDG concentration on PET / CT) can be examined by EBUS, thoracoscopy or
             mediastinoscopy, further sampling is required for pathological confirmation.

          7. Male or female, ≥ 18 years old

          8. Adequate blood function: absolute neutrophil count (ANC) ≥ 2 × 109 / L, platelet count
             ≥ 100 × 109 / L and hemoglobin 110 ≥ 9 g / dl

          9. Adequate liver function: total bilirubin ≤ upper limit of normal value (ULN); AST and
             alt ≤ upper limit of normal value (ULN); alkaline phosphatase ≤ upper limit of normal
             value (ULN)

         10. Adequate renal function: serum creatinine ≤ upper limit of normal value (ULN) or
             calculated creatinine clearance ≥ 60ml / min

         11. No anti-tumor drug treatment in the past

         12. For patients who have had previous surgery, it is required that more than 4 weeks have
             passed since the start of study treatment, and the patients have recovered

         13. Women with a full uterus must have negative pregnancy test results within 28 days
             before entering the study (unless it is 24 months after amenorrhea). If the pregnancy
             test is more than 7 days from the first administration, a urine pregnancy test is
             required for verification (within 7 days before the first administration)

         14. Sign the informed consent form (the informed consent form needs to be approved by the
             independent ethics committee, and the informed consent of the patient should be
             obtained before starting any substantive trial procedure)

        Exclusion Criteria:

          1. Have other malignant tumors in the last 5 years

          2. AST and / or ALT ＞ 2.5 times of the upper limit of normal value (ULN), with alkaline
             phosphatase ＞ 5 times of the upper limit of normal value (ULN)

          3. Previously received radiotherapy

          4. Previously used chemotherapy drugs, targeted and immunotherapy drugs (except
             bisphosphonates)

          5. There are any uncontrolled systemic diseases, including active infection, uncontrolled
             hypertension, diabetes, unstable angina, congestive heart failure, myocardial
             infarction (within 1 year before treatment), serious arrhythmia requiring drug
             treatment, liver, kidney and metabolic diseases

          6. Women in pregnancy or lactation

          7. The patient (male or female) has the possibility of childbearing but is unwilling or
             does not take effective contraceptive measures

          8. Receive the experimental treatment of other clinical studies at the same time (in the
             treatment period of clinical studies)

          9. Known to be allergic to possible chemotherapy drugs

         10. There is evidence of other diseases, neurological or metabolic dysfunction, abnormal
             physical examination or laboratory examination, and it is suspected that there may be
             a high risk of contraindications to the study drug or complications related to
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Lu</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shun D Lu</last_name>
    <phone>86-21-62821990</phone>
    <phone_ext>15216769608</phone_ext>
    <email>shunlu@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaxian Yao</last_name>
    <phone>15216769608</phone>
    <email>yaxianyao@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department, Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaxian Yao</last_name>
      <phone>15216769608</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Lu Shun</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

